Daniel Karp has been appointed executive vice president, corporate development at Biogen. Mr. Karp will lead the newly created corporate development function, which will include corporate and business development and corporate strategy. He will be a member of the Executive Committee and report to Michel Vounatsos, Biogen’s chief executive officer.  

“We are very pleased to welcome Daniel to Biogen as we continue our journey as pioneers in neuroscience,” Mr. Vounatsos said. “Daniel’s solid experience from Pfizer combined with his scientific and business education will serve him well in this exciting position as we aim to further build our pipeline and portfolio to tackle unmet needs in neurological diseases.”

Most recently, Mr. Karp served as vice president, Worldwide Business Development and head of business development for R&D at Pfizer. In that role, he led a global team responsible for early science transactions, partnerships and acquisitions across Pfizer’s research portfolio. For more than a decade at Pfizer he held corporate and business development roles spanning rare diseases, gene therapy, vaccines, oncology and specialty care, with experience including mergers and acquisitions, licensing and scientific collaborations. In recent years, he has been involved in several high-profile acquisitions and led business development organizations that executed hundreds of agreements, licenses and collaborations.

“It’s a privilege to join Biogen, a true leader in neuroscience,” Mr. Karp said.  “I’m excited to work with Biogen’s innovative and talented team as we work to expand the company’s portfolio of therapies for people living with serious neurodegenerative diseases.”